MedImmune to Present at CSFB 2003 Health Care Conference
2 mensagens
|Página 1 de 1
MedImmune to Present at CSFB 2003 Health Care Conference
PR Newswire - November 07, 2003 10:34
GAITHERSBURG, Md., Nov 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- MedImmune, Inc. (Nasdaq: MEDI) announced today that it will present at the CSFB 2003 Health Care Conference at 11:00 a.m. Eastern time on November 14, 2003.
The conference is being held at The Arizona Biltmore Resort & Spa in Phoenix, Arizona. MedImmune's presentation will be webcast live for investors at www.medimmune.com and available for replay for a period of 30 days following the conference.
MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. MedImmune actively markets four products, Synagis(R) (palivizumab), FluMist(TM) (Influenza Virus Vaccine Live, Intranasal), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune globulin intravenous (human)), and has additional products in clinical testing. MedImmune employs approximately 1,700 people, is headquartered in Gaithersburg, Maryland, and has additional operations in Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom and the Netherlands. For more information on MedImmune, and for full prescribing information on MedImmune's products, visit the company's website at www.medimmune.com.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
SOURCE MedImmune, Inc.
Media: Jamie Lacey, +1-240-632-4035, or Investors: Will
Roberts, +1-301-527-4358, John Filler, +1-240-632-4086, all of MedImmune,
Inc.
http://www.medimmune.com
Copyright (C) 2003 PR Newswire. All rights reserved.
GAITHERSBURG, Md., Nov 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- MedImmune, Inc. (Nasdaq: MEDI) announced today that it will present at the CSFB 2003 Health Care Conference at 11:00 a.m. Eastern time on November 14, 2003.
The conference is being held at The Arizona Biltmore Resort & Spa in Phoenix, Arizona. MedImmune's presentation will be webcast live for investors at www.medimmune.com and available for replay for a period of 30 days following the conference.
MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. MedImmune actively markets four products, Synagis(R) (palivizumab), FluMist(TM) (Influenza Virus Vaccine Live, Intranasal), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune globulin intravenous (human)), and has additional products in clinical testing. MedImmune employs approximately 1,700 people, is headquartered in Gaithersburg, Maryland, and has additional operations in Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom and the Netherlands. For more information on MedImmune, and for full prescribing information on MedImmune's products, visit the company's website at www.medimmune.com.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
SOURCE MedImmune, Inc.
Media: Jamie Lacey, +1-240-632-4035, or Investors: Will
Roberts, +1-301-527-4358, John Filler, +1-240-632-4086, all of MedImmune,
Inc.
http://www.medimmune.com
Copyright (C) 2003 PR Newswire. All rights reserved.
scuba
Fear blind us the opportunity, greed blind us the danger!
Fear blind us the opportunity, greed blind us the danger!
- Mensagens: 1300
- Registado: 10/11/2002 1:03
- Localização: 24
2 mensagens
|Página 1 de 1
Quem está ligado:
Utilizadores a ver este Fórum: Bar38, Google [Bot], Google Adsense [Bot], josehenry400, MPCER e 444 visitantes